Tim F.
- Country
- Germany
- Department
- Klinik für Kinderheilkunde und Jugendmedizin
Research Overview
- Phase 2 Randomized Study of Inotuzumab Ozogamicin Monotherapy Versus ALLR3 Regimen in Pediatric High-Risk First Relapse CD22-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
- Evaluation of Temozolomide, Topotecan, and Dinutuximab Beta in High-Risk Relapsed Neuroblastoma: A Multi-Arm, Multi-Stage Platform Trial
- Efficacy and Safety of Intravenous Brincidofovir Versus Cidofovir in Adenovirus Viremia Post-Allogeneic Hematopoietic Cell Transplantation
Data & Insights
Has run more than one trial at 27 of 93 partner sites.
Specializations
Pediatric Oncology
The investigator specializes in treating childhood acute lymphoblastic leukemia, with particular emphasis on high-risk cases requiring innovative therapeutic approaches.
- Pediatric blood cancers
- High-risk leukemia management
- B-cell precursor ALL
Areas of focus include CD22-positive malignancies and bone marrow relapse conditions in young patients.
Immunotherapy Research
Key interests center on targeted immunotherapy treatments for pediatric blood cancers, specifically investigating monotherapy approaches in relapsed cases.
- Antibody-based therapies
- Targeted cancer treatments
- Novel therapeutic strategies
The investigator focuses on developing treatment protocols for patients aged 1 to 18 years with resistant disease forms.
Therapeutic Innovation
Expertise in evaluating comparative treatment approaches for pediatric leukemia, with emphasis on improving outcomes in high-risk patient populations.
- Treatment optimization
- Clinical efficacy assessment
- Pediatric therapy protocols
Special interest in developing superior therapeutic strategies for resistant and relapsed leukemia cases.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.